Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-15

Prokidney Corp. (PROK) Stock Forecast Oct. 15, 2026

Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D ▲ Bullish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Top 35% of 5111 stocks scored
Rank correlation · 90D 0.0% Spearman, 358 dates
Market Cap $442M small-cap · #60 of 60 peers
Summary

Prokidney Corp. (PROK) stock forecast summary

Our AI ranks Prokidney Corp. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Prokidney Corp. is a small-cap company with a market capitalization of $442M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.

For PROK, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 0.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, PROK included.

Follow PROK free
Price

PROK price chart and AI forecast

PROK
Cross-section · 2026-10-15

How PROK ranks among 5111 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Prokidney Corp. (PROK) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.

Valuation & Market

MetricPROKIndustry medianRank
Market Cap $442M $2.43B 60/60
Revenue/Share $0.00 – –
FCF/Share $-0.53 – –

Profitability & Margins

MetricPROKIndustry medianRank
Tax Rate 0.6% – –

Financial Health

MetricPROKIndustry medianRank
Current Ratio 8.36x 5.72x 21/59
Interest Coverage -2995.5x -18.1x 34/39
Working Capital $167M $450M 51/59

Cash Flow

MetricPROKIndustry medianRank
Operating Cash Flow -$141M -$132M 32/57
Free Cash Flow -$160M -$107M 30/49
Capital Spending -$19M -$7M 35/49
FCF/Sales -19527.4% -7.8% 31/31
CapEx/Sales 2269.8% 3.9% 1/31

Operational Efficiency

MetricPROKIndustry medianRank
Fixed Assets Turnover 0.0x 4.2x 35/36

Income Statement

MetricPROKIndustry medianRank
Total Revenue $820K $406M 35/36
Operating Income -$177M -$180M 27/54
Net Income -$98M -$155M 22/52
R&D Expense $131M $199M 37/56

Dividend & Shareholder Information

MetricPROKIndustry medianRank
Shares Outstanding 301M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$190M
Cash & Short-term Investments$75M
Total Liabilities$13M
Short-term Debt$21M
Quarterly Financial Reports

PROK quarterly financials and insider trading

Industry Peers · Biological Products, (No Diagnostic Substances)

Prokidney Corp. (PROK) industry peers

Companies classified under the same SEC industry code as Prokidney Corp. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
PROK Prokidney Corp. ▲ $442M – –
AMGN Amgen Inc ▼ $234.65B 27.0x 20.1x
GILD Gilead Sciences, Inc. ▲ $190.38B – 16.1x
MRNA Moderna, Inc. ▲ $90.35B – 13.4x
ARGX Argenx Se ▼ $52.37B 22.2x –
RVMD Revolution Medicines, Inc. ▲ $41.48B – 15.9x
BIIB Biogen Inc. ▼ $34.53B 25.3x 1.9x
BNTX Biontech Se ▲ $22.81B 2.3x –
EXEL Exelixis, Inc. ▶ $15.11B 17.6x 8.2x
NBIX Neurocrine Biosciences Inc ▲ $13.82B 19.7x 3.7x
HALO Halozyme Therapeutics, Inc. ▶ $13.26B 26.9x 92.4x
TECH Bio-Techne Corp ▼ $11.37B 62.5x 5.4x
IBRX Immunitybio, Inc. ▲ $10.50B – –
RGEN Repligen Corp ▶ $10.06B 258.2x 4.8x
PCVX Vaxcyte, Inc. ▲ $10.05B – 3.6x
QGEN Qiagen N.V. ▶ $9.88B 32.3x 2.6x
KRYS Krystal Biotech, Inc. ▶ $9.79B 41.5x 7.2x
TWST Twist Bioscience Corp ▲ $9.29B – 20.8x
KYMR Kymera Therapeutics, Inc. ▲ $8.88B – 5.9x
IOVA Iovance Biotherapeutics, Inc. ▲ $6.44B – 8.8x
IMVT Immunovant, Inc. ▲ $5.76B – 7.8x
CGON Cg Oncology, Inc. ▲ $5.48B – 5.3x
KOD Kodiak Sciences Inc. ▲ $5.10B – 83.4x
CRSP Crispr Therapeutics Ag ▲ $4.86B – 2.8x
SRRK Scholar Rock Holding Corp ▲ $4.82B – 19.0x
ADPT Adaptive Biotechnologies Corp ▲ $4.08B – 28.6x
RLAY Relay Therapeutics, Inc. ▲ $3.74B – 4.2x
TARS Tarsus Pharmaceuticals, Inc. ▲ $3.17B – 9.2x
DNLI Denali Therapeutics Inc. ▼ $2.86B – 3.4x
BEAM Beam Therapeutics Inc. ▲ $2.55B 98.9x 2.4x
LIFE Atyr Pharma Inc ▲ $2.46B – 50.5x
ADMA Adma Biologics, Inc. ▼ $2.40B 17.3x 5.9x
RXRX Recursion Pharmaceuticals, Inc. ▲ $2.25B – 2.5x
NVAX Novavax Inc ▲ $2.08B – –
VCEL Vericel Corp ▲ $2.06B 85.1x 5.6x
BCRX Biocryst Pharmaceuticals Inc ▲ $2.05B – –
ALVO Alvotech ▲ $1.90B – –
MESO Mesoblast Ltd ▶ $1.77B – –
VIR Vir Biotechnology, Inc. ▲ $1.76B – 1.8x
IMCR Immunocore Holdings Plc ▶ $1.46B – 3.5x
MAZE Maze Therapeutics, Inc. ▲ $1.46B – 3.2x
COAG Hemab Therapeutics Holdings, Inc. ▼ $1.40B – 3.1x
SCNI Scinai Immunotherapeutics Ltd. ▶ $1.22B – 155.4x
TSHA Taysha Gene Therapies, Inc. ▲ $1.14B – 3.0x
VOR Vor Biopharma Inc. ▶ $1.11B – –
REPL Replimune Group, Inc. ▲ $1.07B – 10.2x
JATT Zura Bio Ltd ▶ $994M – 5.0x
VALN Valneva Se ▼ $965M – –
IMTX Immatics N.V. ▲ $938M – –
MGTX Meiragtx Holdings Plc ▶ $904M 12.2x 4.2x
CGEM Cullinan Therapeutics, Inc. ▲ $878M – 2.7x
GLUE Monte Rosa Therapeutics, Inc. ▲ $839M – 1.7x
ODTX Odyssey Therapeutics, Inc. ▲ $798M – 1.9x
DNA Ginkgo Bioworks Holdings, Inc. ▲ $776M – 1.9x
SANA Sana Biotechnology, Inc. ▲ $698M – 4.5x
CADL Candel Therapeutics, Inc. ▲ $682M – 5.4x
FDMT 4d Molecular Therapeutics, Inc. ▲ $674M – 1.7x
AURA Aura Biosciences, Inc. ▲ $657M – 2.1x
SLDB Solid Biosciences Inc. ▲ $586M – 1.6x
PRME Prime Medicine, Inc. ▲ $568M – 14.3x

Where PROK sits on the market map

Life Sciences · Biological Products, (No Diagnostic Substances)
Explore the map →
News

Prokidney Corp. (PROK) stock news

Loading...

FAQ

Prokidney Corp. (PROK) stock forecast FAQ

What is the Prokidney Corp. (PROK) stock forecast?

Our AI ranks Prokidney Corp. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Prokidney Corp. stock predictions?

For PROK, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 0.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Prokidney Corp. forecasts updated?

Prokidney Corp. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.

Which companies are Prokidney Corp.'s industry peers?

60 issuers in our coverage, PROK included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.